Kyverna reports durable Phase 1 miv-cel results in progressive MS
+1 new source since this summary was written
Kyverna Therapeutics reported updated Phase 1 findings for single-dose miv-cel in progressive multiple sclerosis on October 23, 2026. In a six-patient Stanford study, all five patients with efficacy data had stable or improved disability scores, while four maintained benefit through one year and the first treated patient remained improved beyond two years. Kyverna also reported CNS CAR T-cell penetration, no high-grade CRS, RMAT designation for non-active SPMS, and a development-strategy update expected by early 2027.
Why it matters
The findings are preliminary and require confirmation in larger controlled trials, according to Stanford's Jeffrey Dunn. The RMAT designation changes the program's regulatory status, while Kyverna's planned development-strategy update by early 2027 is the next stated milestone.
Key facts
- 1Stanford's open-label study treated six patients with either 33M or 100M CAR T-cell dose levels. stocktitan.net
- 2Four patients with more than one-year of follow-up sustained improvement without further chronic immunotherapy. stocktitan.net
- 3CAR T-cell levels in cerebrospinal fluid peaked at approximately day 14, and CD19-positive peripheral B-cell depletion was followed by repopulation beginning at month 3. stocktitan.net
- 4The company reported no high-grade CRS and no cases of ICANS or IEC-HS. stocktitan.net
- 5Kyverna received RMAT designation for non-active secondary progressive multiple sclerosis. investing.com
Summary written by AlphAI AI Desk from 4 of 4 sources. Not investment advice. Figures are as stated by the linked sources.